Amphion pumps $1m into US medical imaging company:
This article was originally published in Clinica
London, UK-based life science company Amphion Innovations has invested $1m to up its stake in Supertron Technologies, a private US medical imaging firm, to 30%. Spun out from New York's Columbia University, Supertron is currently developing a range of next-generation MRI (magnetic resonance imaging) scanners used for neuro- and pre-clinical imaging. According to Amphion, Supertron's scanners offer enhanced quality images more quickly and at a lower cost than conventional MRI devices. The Newark, New Jersey company - headed by Richard Hullihen, formerly of GEC-Picker International and Marconi Medical Systems - is also targeting emerging MRI research applications in the fields of molecular imaging, image-guided therapeutics, image-guided surgery and orthopaedics imaging.
You may also be interested in...
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.